To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. PCSK9 inhibitors enable high risk patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia to achieve Canadian guideline recommended lipid treatment targets. Only a minority of patients are able to benefit from this therapy. Some reasons include lack of affordability and patient reluctance to embrace a new treatment.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with D.
Contact D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack